IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that on June 18, 2026, it received written notice from Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintai